AMGN Amgen Inc

Price (delayed)

$241.91

Market cap

$138.99B

P/E Ratio

19.89

Dividend/share

$6.72

EPS

$12.16

Enterprise value

$165.56B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. ...

Highlights
The P/E is 19% below the 5-year quarterly average of 24.4
The revenue has grown by 5% year-on-year
AMGN's quick ratio is down by 11% since the previous quarter but it is up by 5% year-on-year
The net income has contracted by 8% YoY and by 2.5% from the previous quarter
AMGN's gross margin is down by 5% year-on-year

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
574.55M
Market cap
$138.99B
Enterprise value
$165.56B
Valuations
Price to earnings (P/E)
19.89
Price to book (P/B)
14.97
Price to sales (P/S)
5.55
EV/EBIT
18.05
EV/EBITDA
13.02
EV/Sales
6.58
Earnings
Revenue
$25.16B
EBIT
$9.17B
EBITDA
$12.72B
Free cash flow
$9.84B
Per share
EPS
$12.16
Free cash flow per share
$17.05
Book value per share
$16.16
Revenue per share
$43.61
TBVPS
$55.32
Balance sheet
Total assets
$62.54B
Total liabilities
$53.21B
Debt
$32.69B
Equity
$9.33B
Working capital
$8.43B
Liquidity
Debt to equity
3.5
Current ratio
1.66
Quick ratio
1.16
Net debt/EBITDA
2.09
Margins
EBITDA margin
50.5%
Gross margin
75.6%
Net margin
28.2%
Operating margin
35.4%
Efficiency
Return on assets
11.1%
Return on equity
70.2%
Return on invested capital
19.6%
Return on capital employed
18.5%
Return on sales
36.4%
Dividend
Dividend yield
2.78%
DPS
$6.72
Payout ratio
55.3%

AMGN stock price

How has the Amgen stock price performed over time
Intraday
0.86%
1 week
1%
1 month
-3.77%
1 year
6.63%
YTD
5.21%
QTD
-2.77%

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$25.16B
Gross profit
$19.03B
Operating income
$8.91B
Net income
$7.09B
Gross margin
75.6%
Net margin
28.2%
The net margin has declined by 12% year-on-year
The company's operating margin fell by 11% YoY
The net income has contracted by 8% YoY and by 2.5% from the previous quarter
AMGN's operating income is down by 7% year-on-year and by 2.5% since the previous quarter

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
19.89
P/B
14.97
P/S
5.55
EV/EBIT
18.05
EV/EBITDA
13.02
EV/Sales
6.58
The P/E is 19% below the 5-year quarterly average of 24.4
AMGN's EPS is down by 5% year-on-year
The stock's price to book (P/B) is 65% more than its 5-year quarterly average of 9.0 and 5% more than its last 4 quarters average of 14.1
The revenue has grown by 5% year-on-year
The P/S is 3.5% less than the last 4 quarters average of 5.7

Efficiency

How efficient is Amgen business performance
The ROIC has contracted by 15% YoY and by 4.9% from the previous quarter
AMGN's return on sales is down by 14% year-on-year
AMGN's return on assets is down by 13% year-on-year and by 2.6% since the previous quarter
The ROE has contracted by 7% YoY and by 2.1% from the previous quarter

Dividends

What is AMGN's dividend history
DPS
$6.72
Dividend yield
2.78%
Payout ratio
55.3%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 18% more than its total liabilities
AMGN's quick ratio is down by 11% since the previous quarter but it is up by 5% year-on-year
Amgen's current ratio has decreased by 8% from the previous quarter but it has increased by 4.4% YoY
AMGN's debt to equity is up by 4.2% YoY
The debt rose by 2.6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.